11X Stock Market Accelerator Summit

Eric Fry reveals how an A.I.-based secret could make you up to 11 times RICHER on the same stocks you’re investing in now… without using options, leverage, or anything risky.

Wed, September 27 at 8:00PM ET

Red-Hot IPOF Stock Will Stop Trading Oct. 14. Here’s Why.


  • Chamath Palihapitya announced that Social Capital Hedosophia VI (IPOF) failed to find a target.
  • The billionaire investor attributed valuation and volatility as reasons for returning funds to shareholders.
  • IPOF stock is now trading at its initial public offering price of $10.
IPOF stock - Red-Hot IPOF Stock Will Stop Trading Oct. 14. Here’s Why.

Source: iQoncept/ShutterStock.com

Shares of special purpose acquisition company (SPAC) Social Capital Hedosophia VI (NYSE:IPOF) are falling back to their initial public offering price of $10 after Chamath Palihapitiya announced that he would return all funds to IPOF stock holders.

Palihapitiya explained his team evaluated more than 100 potential targets, but they ultimately stepped away due to two reasons. The first reason was valuation. He noted there were several interesting targets, although a deal “would have required us stretching on price or buying an inferior asset.”

The second reason was the volatile state of the market. Several company’s management teams were hesitant to go public in a downturn year ravaged by inflation, interest rate hikes and supply chain issues.

IPOF Stock Fails to Find a Target

Now, IPOF is set to return capital to its shareholders by Oct. 14, the deadline to find a target. Furthermore, it seems the hype around SPACs has cooled off. Palihapitiya isn’t alone, though. More than 600 SPACs that hold a combined $174 billion are nearing deadlines to find a target over the next 16 months. These may find a fate similar to IPOF if no target is found.

On the other hand, the billionaire investor found success with some of his other SPACs. He successfully took companies like Opendoor (NASDAQ:OPEN), SoFi (NASDAQ:SOFI) and Clover Health (NASDAQ:CLOV) public. Still, all three of these companies are down by more than 40% year-to-date (YTD), with OPEN having the greatest YTD loss of 75%. The large losses on these former SPACs may have scared off potential targets of IPOF.

Palihapitiya noted his opinion on SPACs has remained unchanged since his first deal was signed. He views them as “just one of many tools in our toolkit to support companies as they enter subsequent stages of growth.”

In the meantime, Palihapitiya will focus on targets for his two remaining Bio 2.0 SPACs. Four Bio 2.0 SPACs were launched, while two have already found targets in the form of ProKidney (NASDAQ:PROK) and Akili (NASDAQ:AKLI). In an earlier interview, he disclosed that Social Capital had made $750 million from SPACs, roughly doubling their initial investment.

On the date of publication, Eddie Pan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Eddie Pan specializes in institutional investments and insider activity. He writes for InvestorPlace’s Today’s Market team, which centers on the latest news involving popular stocks.

Article printed from InvestorPlace Media, https://investorplace.com/2022/09/red-hot-ipof-stock-will-stop-trading-oct-14-heres-why/.

©2023 InvestorPlace Media, LLC